“并购之王”初露峥嵘,中国pharma新时代开启

钛媒体
17 Jul

文 | 氨基观察“中国版的罗氏收购基因泰克”,这几天来自中国生物医药行业一个重磅并购,甚至吸引了全球的关注。7月15日,港股医药龙头中国生物制药(01177.HK)宣布将以约10亿美元的估值收购来自上海的生物科技公司礼新医药100%股权。这起中国大型制药企业(Big Pharma)对生物科技公司(Biotech)的并购案,迅速吸引了彭博社、路透社、Fierce Biotech等多家海外权威财经与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10